bioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® Lung

Go back to bioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® Lung
(NASDAQ: BIAF) Delayed: 8.93 -6.34 (41.52%)
Previous Close $15.27    52 Week High
Open $10.63    52 Week Low
Day High $10.63    P/E N/A 
Day Low $8.36    EPS
Volume 2,405,595       

(NASDAQ: BIAFW) Delayed: 0.60 -0.1 (14.29%)
Previous Close $0.70    52 Week High
Open $0.98    52 Week Low
Day High $0.98    P/E N/A 
Day Low $0.55    EPS
Volume 48,446